US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily S&P Biotech Bull 3x Shares

297.76

+1.450.49%

Volume:141.31K

Turnover:41.67M

Market Cap:573.03M

PE:- -

High:299.60

Open:291.05

Low:289.32

Close:296.31

52wk High:341.93

52wk Low:71.88

Shares:1.92M

Float Shares:1.92M

Volume Ratio:0.70

T/O Rate:7.34%

Dividend:1.01

Dividend Rate:0.34%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Inspire Medical Systems, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference

NextNRG Secures 25-Year Microgrid Contract with Taft Medical Complex, Expanding Its Healthcare Infrastructure Model into Florida

Celcuity Files sNDA to Expand REVTORPYK Breast Cancer Use

Celcuity submits Revtorpyk sNDA to the FDA

Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer

Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

InnovAge Announces Conference Call to Discuss Fourth Quarter and Fiscal 2026 Financial Results and Participation in Upcoming Wells Fargo Healthcare Conference

COMPASS Pathways (CMPS) Nears FDA Filing for COMP360 Following a Valuation Question

Simply Wall St.

Analysts Offer Insights on Healthcare Companies: Solventum Corporation (SOLV), Argenx Se (ARGX) and Spyre Therapeutics (SYRE)

CSPC Pharma's SYS6090 (JMT108) Receives FDA Fast Track Designation for MSS/pMMR Metastatic Colorectal Cancer Treatment

Jiangsu Unveils Plan to Encourage Inclusion of Innovative Drugs in Commercial Health Insurance and Mutual Aid Coverage

IHH Healthcare Completes Voluntary Liquidation of Subsidiary

MT Newswires Live

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and GoodRx Holdings (GDRX)

Health Care Roundup: Market Talk

Nxera to Book US$10m Milestone as FDA Clears Phase 2 Alzheimer’s Drug

Barclays Appoints Ramin Naji to Lead Healthcare and Property Investment Banking Across Asia-Pacific

Foundation Healthcare's Growth Supported by Rising Healthcare Utilization

Johnson & Johnson (JNJ) Wins FDA Approval For First Warm Autoimmune Hemolytic Anemia Treatment

Simply Wall St.

Analysts Have Conflicting Sentiments on These Healthcare Companies: Nanosonics Limited (OtherNNCSF) and Innovent Biologics (OtherIVBXF)

Neuropace Earnings Call Shows Strong Growth Amid FDA Risk

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/LABU/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"Direxion Daily S&P Biotech Bull 3x Shares","latestPrice":297.76,"timestamp":1788282374397,"preClose":296.31,"halted":0,"volume":141307,"delay":0,"changeRate":0.004893523674530015,"floatShares":1924486,"shares":1924486,"eps":0,"marketStatus":"Trading","change":1.45,"latestTime":"09-01 13:07:33 EDT","open":291.05,"high":299.595,"low":289.32,"amount":41673395.641160004,"amplitude":0.034677,"askPrice":297.9,"askSize":40,"bidPrice":297.21,"bidSize":330,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788292800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":296.31,"sharesOutstanding":3074486,"nav":295.545,"aum":568772231.45,"dividendRate":0.003384,"bidAskSpread":0.002847,"preHourTrading":{"tag":"盘前","latestPrice":287.9,"preClose":296.31,"latestTime":"09:25 EDT","volume":3856,"amount":1113924.82752,"timestamp":1788269101054,"change":-8.41,"changeRate":-0.028382,"amplitude":0.034741},"postHourTrading":{"tag":"盘后","latestPrice":295.02,"preClose":296.31,"latestTime":"19:59 EDT","volume":2518,"amount":745089.4272,"timestamp":1788220773434,"change":-1.29,"changeRate":-0.004354,"amplitude":0.010268},"volumeRatio":0.701358,"impliedVol":0.924,"impliedVolPercentile":0.5595},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":1924486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.701358,"shares":1924486,"dividePrice":1.0075,"high":299.595,"amplitude":0.034677,"preClose":296.31,"low":289.32,"week52Low":71.88,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":297.76,"committee":0.783784,"eps":0,"divideRate":0.003384,"volume":141307,"delay":0,"ttmEps":0,"open":291.05,"prevYearClose":159.39,"prevWeekClose":295.76,"prevMonthClose":296.31,"prevQuarterClose":292.1,"fiveDayClose":335.54,"twentyDayClose":249.47,"sixtyDayClose":160.26},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662126847","title":"Inspire Medical Systems, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2662126847","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662126847?lang=en_us&edition=fundamental","pubTime":"2026-08-26 21:15","pubTimestamp":1787750100,"startTime":"0","endTime":"0","summary":"MINNEAPOLIS, Aug.  26, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minim","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/26/3351428/0/en/inspire-medical-systems-inc-to-present-at-the-wells-fargo-21st-annual-healthcare-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1074936037.SGD","XBI","LU1894683264.USD","LU1814569148.SGD","LU0029874061.USD","LU0742534661.SGD","LU0154236417.USD","KBWB","INSP","LU2361045086.USD","HCSG","LU0971096721.USD","LU1267930573.SGD","LU0310800379.SGD","LU0417517546.SGD","LU0211327993.USD","FTXO","LU0128526141.USD","LU0128525689.USD","LU0128525929.USD","BK4559","LU1894683348.USD","IE00B19Z3581.USD","BK4588","LU0320765489.SGD","LU2461242641.AUD","LU0708994859.HKD","LU0130102774.USD","LU2065731478.USD","LU0868494617.USD","LU0130517989.USD","LU1363072403.SGD","LU1668664300.SGD","LU0162691827.USD","BK4582","LU0314106906.USD","LABU","LU0175139822.USD","TFNS","LU0683600562.USD","XLV","LU1506573853.SGD","IYF","LU0256863811.USD","BK4167","PGF","LU0868494708.USD","LU0029864427.USD","LU1267930227.SGD","LU0942090050.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662714232","title":"NextNRG Secures 25-Year Microgrid Contract with Taft Medical Complex, Expanding Its Healthcare Infrastructure Model into Florida","url":"https://stock-news.laohu8.com/highlight/detail?id=2662714232","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662714232?lang=en_us&edition=fundamental","pubTime":"2026-08-26 21:00","pubTimestamp":1787749200,"startTime":"0","endTime":"0","summary":"Agreement helps Taft Medical Complex meet Florida's 96-hour backup power healthcare mandate while extending NextNRG's repeatable, own-and-operate energy modelMIAMI, FL, Aug.  26, 2026 (GLOBE NEWSWIRE)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/26/3351368/0/en/nextnrg-secures-25-year-microgrid-contract-with-taft-medical-complex-expanding-its-healthcare-infrastructure-model-into-florida.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0029874061.USD","BK4137","CGCV","NOBL","BK4550","HCSG","XBI","XLV","IXJ","BK4588","LU0128526141.USD","VHT","BK4581","TCAF","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662714938","title":"Celcuity Files sNDA to Expand REVTORPYK Breast Cancer Use","url":"https://stock-news.laohu8.com/highlight/detail?id=2662714938","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662714938?lang=en_us&edition=fundamental","pubTime":"2026-08-26 20:57","pubTimestamp":1787749076,"startTime":"0","endTime":"0","summary":"The latest update is out from Celcuity ( ($CELC) ). On August 26, 2026, Celcuity submitted a supplemental New Drug Application to the U.S. FDA seek...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/celcuity-files-snda-to-expand-revtorpyk-breast-cancer-use?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/celcuity-files-snda-to-expand-revtorpyk-breast-cancer-use?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662714613","title":"Celcuity submits Revtorpyk sNDA to the FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2662714613","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662714613?lang=en_us&edition=fundamental","pubTime":"2026-08-26 20:40","pubTimestamp":1787748023,"startTime":"0","endTime":"0","summary":"Celcuity (CELC) announced the submission of its supplemental new drug application, or sNDA, to the FDA for Revtorpyk for the treatment of patients ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/celcuity-submits-revtorpyk-snda-to-the-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/celcuity-submits-revtorpyk-snda-to-the-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","CELC","BK4588","BK4139","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662471428","title":"Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2662471428","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662471428?lang=en_us&edition=fundamental","pubTime":"2026-08-26 20:30","pubTimestamp":1787747400,"startTime":"0","endTime":"0","summary":"If approved, REVTORPYK would be the first and only therapy for advanced breast cancer with a PIK3CA mutation that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2 M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/26/3351327/0/en/celcuity-submits-snda-to-fda-for-revtorpyk-gedatolisib-for-hr-her2-pik3ca-mutant-locally-advanced-or-metastatic-breast-cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEIS","BK4225","BK4157","LU1815336091.USD","BK4599","BK4139","BK4585","LABU","IE00B19Z4B17.USD","MEDX","IDNA","BK4203","GDOC","LU1878469433.USD","LU2931357623.SGD","IE0031619046.USD","LU2089985449.USD","LU0757428866.USD","HR","BK4588","SRET","ALT","IE00B7SZL793.SGD","HYLG","LU0274383776.USD","IE00B66KJ199.SGD","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662822719","title":"Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2662822719","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662822719?lang=en_us&edition=fundamental","pubTime":"2026-08-26 20:00","pubTimestamp":1787745600,"startTime":"0","endTime":"0","summary":"RADNOR, Pa., Aug.  26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/26/3351282/0/en/mineralys-therapeutics-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FTXO","LU0162691827.USD","BK4007","PGF","KBWB","XLV","XBI","LU0208291251.USD","LU0128525689.USD","BK4585","LU0971096721.USD","LU0154236417.USD","LU0648001328.SGD","LU0640476718.USD","HCSG","LU1506573853.SGD","LU1814569148.SGD","LU2461242641.AUD","LU2361045086.USD","LU0289960550.SGD","LU0211328371.USD","LU0868494617.USD","LU1894683348.USD","BK4504","IYF","BK4501","BK4559","LU2361044949.HKD","LU0417517546.SGD","LU0211327993.USD","LU0251142724.SGD","LU1668664300.SGD","BK4581","LU1035773651.USD","LU0106831901.USD","BK4588","TFNS","LU0130102774.USD","LU1791807156.HKD","LU0320765489.SGD","LU0683600562.USD","LU0267386448.USD","LABU","BK4137","LU0048573561.USD","LU0070302665.USD","LU0868494708.USD","IE0002270589.USD","LU0128526141.USD","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662719849","title":"InnovAge Announces Conference Call to Discuss Fourth Quarter and Fiscal 2026 Financial Results and Participation in Upcoming Wells Fargo Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2662719849","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662719849?lang=en_us&edition=fundamental","pubTime":"2026-08-26 20:00","pubTimestamp":1787745600,"startTime":"0","endTime":"0","summary":"DENVER, Aug.  26, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, and predomin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/26/3351255/0/en/innovage-announces-conference-call-to-discuss-fourth-quarter-and-fiscal-2026-financial-results-and-participation-in-upcoming-wells-fargo-healthcare-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0162691827.USD","LU1363072403.SGD","LU1814569148.SGD","XLV","LU0683600562.USD","LU2361044949.HKD","LU0106831901.USD","IE00B19Z3581.USD","LU0742534661.SGD","LU0868494708.USD","LU1894683348.USD","FTXO","BK4585","LU0208291251.USD","BK4504","LU1267930227.SGD","BK4581","IYF","LU0251142724.SGD","BK4137","LU1506573853.SGD","LU0128525689.USD","PGF","LU0640476718.USD","LU0128525929.USD","BK4207","LU0251131958.USD","LU0130517989.USD","LU1668664300.SGD","LU0029874061.USD","LU0154236417.USD","LU0417517546.SGD","BK4582","LU0256863811.USD","LU0980610538.SGD","LU0070302665.USD","LU0130102774.USD","XBI","LU1267930490.SGD","LU1074936037.SGD","LABU","LU0942090050.USD","LU0128526141.USD","LU0477156953.USD","LU0787776722.HKD","BK4588","LU2361045086.USD","HCSG","KBWB","TFNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662113637","title":"COMPASS Pathways (CMPS) Nears FDA Filing for COMP360 Following a Valuation Question","url":"https://stock-news.laohu8.com/highlight/detail?id=2662113637","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662113637?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:26","pubTimestamp":1787743564,"startTime":"0","endTime":"0","summary":"COMPASS Pathways (NasdaqGS:CMPS) is back in focus as investors watch the final stages of its planned FDA application for COMP360, a synthetic psilocybin treatment for people with treatment-resistant depression.\nOver the past year, COMPASS Pathways has seen strong momentum, with a year to date share price return of 127.18% and a 1 year total shareholder return of 212.61%. The recent 32.15% 30 day share price return suggests that enthusiasm around the FDA submission is building further.\nScan...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cmps/compass-pathways/news/compass-pathways-cmps-nears-fda-filing-for-comp360-following","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cmps/compass-pathways/news/compass-pathways-cmps-nears-fda-filing-for-comp360-following","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","PSIL","BK4139","CMPS","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662239718","title":"Analysts Offer Insights on Healthcare Companies: Solventum Corporation (SOLV), Argenx Se (ARGX) and Spyre Therapeutics (SYRE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662239718","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662239718?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:50","pubTimestamp":1787741417,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Solventum Corporation (SOLV), Argenx Se (ARGX) and S...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-solventum-corporation-solv-argenx-se-argx-and-spyre-therapeutics-syre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-solventum-corporation-solv-argenx-se-argx-and-spyre-therapeutics-syre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4198","LU0029874061.USD","TBXU","LU0128526141.USD","LFSC","LU0889565916.HKD","XBI","IE00BJJMRZ35.SGD","BK4137","IE0002141913.USD","SYRE","LU0823416689.USD","BK4505","FMED","LU0320765992.SGD","XLV","LABU","LU1983260115.SGD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","BK4139","IE00BJT1NW94.SGD","BK4581","IE0034235188.USD","SOLV","IE0009355771.USD","IBB","ARGX","BK4585","LU0109394709.USD","BK4588","LU2324357040.USD","HCSG","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119638338","title":"CSPC Pharma's SYS6090 (JMT108) Receives FDA Fast Track Designation for MSS/pMMR Metastatic Colorectal Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1119638338","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119638338?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:18","pubTimestamp":1787739482,"startTime":"0","endTime":"0","summary":"CSPC Pharma (01093) has announced that its first-in-class PD-1/IL-15 bispecific fusion protein, SYS6090 (JMT108), has been granted Fast Track designation by the U.S. Food and Drug Administration...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B031HY20.USD","LU1226287529.USD","BK4585","BK1191","LU1993786604.SGD","LU0140636845.USD","LU1960683339.HKD","LU0326950275.SGD","LU0314109678.HKD","LU1226288253.USD","LU1226287792.SGD","LU1226288170.HKD","LU0501845795.SGD","LU1008478684.HKD","LABU","IE00BZ08YT58.USD","LU1951186391.HKD","01093","IE00BZ08YR35.GBP","LU0067412154.USD","LU0880133367.SGD","IE0008369823.USD","LU1328277881.USD","IE0008368742.USD","LU1226287875.USD","HK0000165453.HKD","LU0072913022.USD","LU1152091168.USD","BK1515","IE00B543WZ88.USD","BK1521","LU2039709279.SGD","LU0315179316.USD","LU1813983027.USD","SG9999004220.SGD","BK4588","BK4113","IE00B5MMRT66.SGD","MSS","LU1807302812.USD","LU1152091754.HKD","KURE","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136653718","title":"Jiangsu Unveils Plan to Encourage Inclusion of Innovative Drugs in Commercial Health Insurance and Mutual Aid Coverage","url":"https://stock-news.laohu8.com/highlight/detail?id=1136653718","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136653718?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:11","pubTimestamp":1787739064,"startTime":"0","endTime":"0","summary":"On August 26, in a financial frontline update, Jiangsu Province issued the \"Three-Year Action Plan for Promoting High-Quality Development of the Biomedical Industry.\" The plan highlights the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","159891","LNGR","BK4588","MEDX","XLV","BK4581","BK1161","XBI","159992","LABU","BK1574","BK4585","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662976847","title":"IHH Healthcare Completes Voluntary Liquidation of Subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2662976847","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662976847?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:10","pubTimestamp":1787739001,"startTime":"0","endTime":"0","summary":"IHH Healthcare (KLSE:IHH) said the voluntary liquidation of Suzhou Industrial Park Yuan Hui Health Consulting has been completed.The subsidiary was deregistered on Aug. 7, according to a Wednesday Malaysian bourse filing.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0029874061.USD","XBI","BK6092","BK4585","LU0128526141.USD","BK4588","BK4581","HCSG","XLV","Q0F.SI","LABU","BK4137","BK6511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662446799","title":"Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and GoodRx Holdings (GDRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662446799","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662446799?lang=en_us&edition=fundamental","pubTime":"2026-08-26 16:50","pubTimestamp":1787734244,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Jazz Pharmaceuticals (JAZZ) and GoodRx Holdings (G...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-jazz-pharmaceuticals-jazz-and-goodrx-holdings-gdrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-jazz-pharmaceuticals-jazz-and-goodrx-holdings-gdrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","JAZZ","LU0889565916.HKD","BK4532","BK4007","BK4581","HCSG","LU0029874061.USD","BK4585","BK4167","IE00BN0W2T93.GBP","BK4533","BK4588","LU0154245673.USD","IE00BN0W2W23.USD","XLV","IE00BN0W2V16.EUR","BK4137","LU0154245756.USD","XBI","GDRX","LABU","LU0109394709.USD","LU0320765992.SGD","LU0823416689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662879650","title":"Health Care Roundup: Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2662879650","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662879650?lang=en_us&edition=fundamental","pubTime":"2026-08-26 16:20","pubTimestamp":1787732400,"startTime":"0","endTime":"0","summary":"The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0743 GMT - WuXi XDC Cayman retains its bull at Citi Research on ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","XLV","XBI","BK4581","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662795913","title":"Nxera to Book US$10m Milestone as FDA Clears Phase 2 Alzheimer’s Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2662795913","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662795913?lang=en_us&edition=fundamental","pubTime":"2026-08-26 15:52","pubTimestamp":1787730745,"startTime":"0","endTime":"0","summary":"Sosei Group ( ($JP:4565) ) has provided an update. Nxera Pharma’s partner Neurocrine Biosciences has secured FDA IND acceptance for a Phase 2 trial...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nxera-to-book-us10m-milestone-as-fda-clears-phase-2-alzheimers-drug?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nxera-to-book-us10m-milestone-as-fda-clears-phase-2-alzheimers-drug?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","IND","BBC","PSIL","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108791824","title":"Barclays Appoints Ramin Naji to Lead Healthcare and Property Investment Banking Across Asia-Pacific","url":"https://stock-news.laohu8.com/highlight/detail?id=1108791824","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108791824?lang=en_us&edition=fundamental","pubTime":"2026-08-26 13:46","pubTimestamp":1787723202,"startTime":"0","endTime":"0","summary":"On August 26, Barclays PLC (BCS.US) announced the appointment of Ramin Naji as Managing Director and Head of Healthcare and Real Estate for the Asia-Pacific region.Based in Hong Kong, Ramin Naji will...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","VHT","BK1148","BK4581","BCS","BK4207","159760","XBI","BK4550","09979","BK4521","LABU","REET","BK4585","IXJ","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662776767","title":"Foundation Healthcare's Growth Supported by Rising Healthcare Utilization","url":"https://stock-news.laohu8.com/highlight/detail?id=2662776767","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662776767?lang=en_us&edition=fundamental","pubTime":"2026-08-26 13:31","pubTimestamp":1787722260,"startTime":"0","endTime":"0","summary":"0531 GMT - Foundation Healthcare Holdings' long growth trajectory is supported by rising healthcare utilization and other tailwinds, Jefferies analysts say in a research report. This tailwind together with ambulatory care adoption and industry consolidation are quickening demand for lower-cost, coordinated care, the analysts say. The company is one of Singapore's largest private specialist platforms, and has a business model that combines specialist practices, medical centers and technology platform 'AVA' that produces benefits such as procurement efficiencies. The company's ambulatory facilities positions it to gain from migration of care out of hospitals. Jefferies initiates coverage of the stock with a buy rating and a target price of 1.10 Singapore dollars. Shares are 4.9% higher at S$0.75.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCSG","BK6100","BK4588","FHH.SI","LU0029874061.USD","BK4137","XLV","BK4581","LABU","XBI","BK4585","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662762864","title":"Johnson & Johnson (JNJ) Wins FDA Approval For First Warm Autoimmune Hemolytic Anemia Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2662762864","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662762864?lang=en_us&edition=fundamental","pubTime":"2026-08-26 11:33","pubTimestamp":1787715187,"startTime":"0","endTime":"0","summary":"Johnson & Johnson (NYSE: JNJ) received FDA approval for IMAAVY as the first treatment for adults with warm autoimmune hemolytic anemia, providing a new option for this rare blood disorder.\nThe decision expands Johnson & Johnson's presence in rare diseases, with IMAAVY targeting patients who face limited existing therapies.\nIn a separate development, a jury awarded a US$10 million verdict in a talc-related mesothelioma case against Johnson & Johnson, adding to its ongoing litigation...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/139677-main-header/1756253951625","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/139677-main-header/1756253951625"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-jnj/johnson-johnson/news/johnson-johnson-jnj-wins-fda-approval-for-first-warm-autoimm","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-jnj/johnson-johnson/news/johnson-johnson-jnj-wins-fda-approval-for-first-warm-autoimm","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["FTXH","BK4588","LU1066053197.SGD","GDOC","SGXZ57979304.SGD","XLV","LU2089984988.USD","JDOC","IE00B4R5TH58.HKD","FHLC","BK4504","IE00BLSP4452.SGD","IE00BSNM7G36.USD","IE000MB6IJN5.SGD","IE0009355771.USD","IE000SO60NU8.SGD","PJP","LU0203345920.USD","LU0964807845.USD","LU1430594728.SGD","LU0792757196.USD","LU1043141123.HKD","LU0058720904.USD","LU0234570918.USD","LU1551013425.SGD","IHE","LU1261432733.SGD","LU1732799900.SGD","LU2112291526.USD","LU1043141396.HKD","JNJ","RXL","MEDX","IYH","LABU","LU2468319806.SGD","LU0426412945.USD","LU0820561909.HKD","TRUH","LU2756315664.SGD","LU1061106388.HKD","IE00BFTCPJ56.SGD","BK4534","LU1935042991.SGD","LU0320765646.SGD","LU1496350502.SGD","LU1914381329.SGD","LU1267930813.SGD","LU2347655156.SGD","LU0345770993.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662766213","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Nanosonics Limited (OtherNNCSF) and Innovent Biologics (OtherIVBXF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662766213","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662766213?lang=en_us&edition=fundamental","pubTime":"2026-08-26 09:40","pubTimestamp":1787708404,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Nanosonics Limited (NNCSF) and Innovent Biologics ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-nanosonics-limited-othernncsf-and-innovent-biologics-otherivbxf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-nanosonics-limited-othernncsf-and-innovent-biologics-otherivbxf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LU0128526141.USD","LABU","NNCSF","BK4581","XLV","XBI","BK4137","HCSG","BK4585","BK4198","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662763907","title":"Neuropace Earnings Call Shows Strong Growth Amid FDA Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2662763907","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662763907?lang=en_us&edition=fundamental","pubTime":"2026-08-26 08:23","pubTimestamp":1787703828,"startTime":"0","endTime":"0","summary":"Neuropace, Inc. (($NPCE)) has held its Q2 earnings call. Read on for the main highlights of the call. Neuropace’s latest earnings call struck a lar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neuropace-earnings-call-shows-strong-growth-amid-fda-risk?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neuropace-earnings-call-shows-strong-growth-amid-fda-risk?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":21,"pageCount":10,"totalSize":406,"code":"91000000","status":"200"}]}}